{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["142(9)"],"submitter":["Huels J"],"pubmed_abstract":["Neisseria meningitidis is the main cause of bacterial meningitis and sepsis in the UK, and can potentially be lethal or cause long-term sequelae. Bexsero® (4CMenB) is a new multi-component vaccine approved by the European Commission for use in individuals aged ⩾2 months. A theoretical transmission model was constructed to assess the long-term effectiveness of Bexsero compared to standard care. The model was populated with UK-specific demographic data and calibrated to ensure that the transmission dynamics of meningococcal disease in the UK were adequately simulated. The model showed the best strategy to be a routine vaccination programme at ages 2, 3, 4, 12 months and 14 years combined with a 5-year catch-up programme in toddlers aged 12-24 months and adolescents aged 15-18 years. This would lead to a 94% reduction in meningococcal cases or 150 000 cases and 15 000 deaths over a 100-year time-frame."],"journal":["Epidemiology and infection"],"pagination":["2000-12"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9506718"],"repository":["biostudies-literature"],"pubmed_title":["Modelled evaluation of multi-component meningococcal vaccine (Bexsero®) for the prevention of invasive meningococcal disease in infants and adolescents in the UK."],"pmcid":["PMC9506718"],"pubmed_authors":["Huels J","Clements KM","Wassil J","Hill GJ","Kessabi S","McGARRY LJ"],"additional_accession":[]},"is_claimable":false,"name":"Modelled evaluation of multi-component meningococcal vaccine (Bexsero®) for the prevention of invasive meningococcal disease in infants and adolescents in the UK.","description":"Neisseria meningitidis is the main cause of bacterial meningitis and sepsis in the UK, and can potentially be lethal or cause long-term sequelae. Bexsero® (4CMenB) is a new multi-component vaccine approved by the European Commission for use in individuals aged ⩾2 months. A theoretical transmission model was constructed to assess the long-term effectiveness of Bexsero compared to standard care. The model was populated with UK-specific demographic data and calibrated to ensure that the transmission dynamics of meningococcal disease in the UK were adequately simulated. The model showed the best strategy to be a routine vaccination programme at ages 2, 3, 4, 12 months and 14 years combined with a 5-year catch-up programme in toddlers aged 12-24 months and adolescents aged 15-18 years. This would lead to a 94% reduction in meningococcal cases or 150 000 cases and 15 000 deaths over a 100-year time-frame.","dates":{"release":"2014-01-01T00:00:00Z","publication":"2014 Sep","modification":"2025-04-04T20:07:17.697Z","creation":"2025-04-04T20:07:17.697Z"},"accession":"S-EPMC9506718","cross_references":{"pubmed":["24284038"],"doi":["10.1017/S095026881300294X","10.1017/s095026881300294x"]}}